1Landry D W, Oliver J A. The pathogenesis of vasodilatory shock. N EnglJ Med, 2001, 345: 588-595.
2Dellinger R P. Cardiovascular management of septic shock. Crit Care Med, 2003, 31: 946-955.
3Dunser M W, Mayr A J, Ulmer H, et al. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation, 2003, 107:2313-2319.
5Treschan T A, Peters J. The vasopressin system: physiology and clinical strategies. Anesthesiology, 2006, 105: 599-612.
6Wenzel V, Lindner K H. Arginine vasopressin during cardiopulmonary resuscitation: laboratory evidence, clinical experience and recommendations, and a view to the future. Crit Care Med, 2002, 30(Suppl 4) : S157-S161.
7Russell J A. Vasopressin in septic shock. Crit Care Med, 2007, 35(Suppl 9):S609-S615.
8Landry D W, Levin H R, Gallant E M, et al. Vasopressin pressor hypersensitivity in vasodilatory septic shock. Crit Care Med, 1997, 25: 1279-1282.
9Landry D W, Levin H R, Gallant E M, et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation, 1997, 95: 1122-1125.
10Oliver J A, Landry D W. Endogenous and exogenous vasopressin in shock. Curr Opin Crit Care, 2007, 13: 376-382.
1Bracco D, Dubois MJ. Hemodynamic support in septic shock: is restoring a normal blood pressure the right target [ J ]. Crit Care Med, 2005,33 (9) :2113-2115.
2Velez JC, Nietert PJ. Therapeutic response to vasoconstrictors in hepator- enal syndrome parallels increase in mean arterial pressure: a pooled anal- ysis of clinical trials [ J ]. Am J Kidney Dis, 2011,58 (6) :928-938.
3Maybauer MO, Maybauer DM. Vasopressin analogues and V1 a receptor agonists in septic shock[J]. Inflamm Res,2011,60(5) :425-427.
4Moreau R, Durand F, Poynard T, et al. Terlipressin in patients with cir- rhosis and type 1 hepatorenal syndrome: a retrospective muhicenter study [ J ]. Gastroenterology,2002,122 (4) :923-930.
